| 1 |
34241984 | Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype. | 2022 May 1 |
3 |
| 2 |
34362271 | The CYP3A5 and ABCB1 Gene Polymorphisms in Kidney Transplant Patients and Establishment of Initial Daily Tacrolimus Dosing Formula. | 2022 Apr |
2 |
| 3 |
34583027 | Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy. | 2022 Jan |
5 |
| 4 |
34688813 | CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation. | 2022 Jan 30 |
3 |
| 5 |
34708436 | Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes. | 2022 Feb |
2 |
| 6 |
34781138 | Trans-eQTLs of the CYP3A4 and CYP3A5 associated with tacrolimus trough blood concentration in Chinese renal transplant patients. | 2022 Jan |
2 |
| 7 |
34859357 | The impact of cytochrome P450 3A5 genotype on early tacrolimus metabolism and clinical outcomes in lung transplant recipients. | 2022 Apr |
4 |
| 8 |
35103348 | Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients. | 2022 Feb |
2 |
| 9 |
35110472 | Pharmacokinetics of tacrolimus following an overdose in a patient with extreme obesity and genotype CYP3A5*3/*3: a case report. | 2022 |
1 |
| 10 |
35180322 | Effect of hepar-protecting Wuzhi capsule on Pharmacokinetics and Dose-effect Character of Tacrolimus in Healthy Volunteers. | 2022 Feb 18 |
3 |
| 11 |
35202484 | PharmVar GeneFocus: CYP3A5. | 2022 Feb 24 |
2 |
| 12 |
35220592 | Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. | 2022 Apr |
1 |
| 13 |
35238110 | Personalized immunosuppression after kidney transplantation. | 2022 Jun |
2 |
| 14 |
35322385 | Correction to: The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients. | 2022 Jun |
1 |
| 15 |
35389944 | Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients. | 2022 Jul 1 |
4 |
| 16 |
35395919 | Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes. | 2022 Mar |
9 |
| 17 |
35428510 | CYP3a5 Genetic Polymorphism in Chinese Population With Renal Transplantation: A Meta-Analysis Review. | 2022 Apr |
2 |
| 18 |
35466485 | Effects of tacrolimus intrapatient variability and CYP3A5 polymorphism on the outcomes of pediatric kidney transplantation. | 2022 Apr 24 |
1 |
| 19 |
35536394 | The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients. | 2022 May 10 |
2 |
| 20 |
35562875 | Examination of the Impact of CYP3A4/5 on Drug-Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach. | 2022 Apr 19 |
1 |
| 21 |
35570009 | Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients-Preliminary Report. | 2022 May 12 |
8 |
| 22 |
35578867 | Impact of POR*28 Variant on Tacrolimus Pharmacokinetics in Kidney Transplant Patients with Different CYP3A5 Genotypes. | 2022 May 16 |
1 |
| 23 |
35629245 | Evaluation of Pharmacogenetics of Drug-Metabolizing Enzymes and Drug Efflux Transporter in Renal Transplants Receiving Immunosuppressants. | 2022 May 19 |
1 |
| 24 |
32803289 | Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. | 2021 Jan |
2 |
| 25 |
32843687 | Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients. | 2021 Feb |
1 |
| 26 |
32986876 | Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A-status in liver transplant recipients. | 2021 Apr |
2 |
| 27 |
33027230 | Tacrolimus Exposure in Obese Patients: and A Case-Control Study in Kidney Transplantation. | 2021 Apr 1 |
1 |
| 28 |
33248001 | Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene. | 2021 Mar |
3 |
| 29 |
33348024 | Multiple microRNAs regulate tacrolimus metabolism through CYP3A5. | 2021 Feb |
5 |
| 30 |
33386894 | The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation. | 2021 Jun |
2 |
| 31 |
33398393 | CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients. | 2021 Jun |
2 |
| 32 |
33432012 | Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. | 2021 Jan 11 |
4 |
| 33 |
33515077 | Correction to: CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic syndrome. | 2021 Aug |
1 |
| 34 |
33649515 | Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients. | 2021 Jun |
1 |
| 35 |
33654003 | Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing. | 2021 Oct 1 |
3 |
| 36 |
33673653 | Investigation of the Impact of CYP3A5 Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. | 2021 Feb 27 |
3 |
| 37 |
33692688 | Commentary: The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. | 2021 |
1 |
| 38 |
33746516 | Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus. | 2021 |
5 |
| 39 |
33751414 | Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials. | 2021 Jul |
1 |
| 40 |
33768546 | Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients. | 2021 Aug |
6 |
| 41 |
33866281 | CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients. | 2021 Jun 15 |
2 |
| 42 |
33920149 | Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion. | 2021 Apr 10 |
6 |
| 43 |
33967795 | CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients. | 2021 |
1 |
| 44 |
34058078 | Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end-stage renal disease. | 2021 Sep |
4 |
| 45 |
34129685 | Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients. | 2021 Aug |
1 |
| 46 |
34290611 | CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. | 2021 |
6 |
| 47 |
34342024 | Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients. | 2021 Dec |
1 |
| 48 |
34352707 | Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms. | 2021 Oct |
1 |
| 49 |
34525930 | Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis. | 2021 |
1 |
| 50 |
34620272 | Tacrolimus and herbs interactions: a review. | 2021 Oct 1 |
1 |